• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Hormone therapy may not prevent atherosclerosis in menopausal women

bySai FolmsbeeandAimme Li, MD
July 28, 2014
in Cardiology, Chronic Disease, Obstetrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized, controlled trial of healthy menopausal women, hormonal therapy did not slow the progression of atherosclerosis. 

2. Depending on the hormonal therapy, there were small improvements to lipoprotein cholesterol levels and insulin resistance. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Cardiovascular disease (CVD) is the leading cause of death in women.  Despite the increased risk of CVD after menopause, it is not known whether menopausal hormone therapy (MHT) can slow its progression. Therefore, the authors performed a randomized, controlled trial of healthy, menopausal women and assigned either hormonal therapy or placebo. Both the carotid artery intima-media thickness (CIMT) and coronary artery calcium (CAC) were assessed as measurements of atherosclerosis.  The study found no significant difference in these measures of atherosclerosis between those that received MHT and placebo. There was also no difference in blood pressure, but depending on the type of hormonal therapy, there were some changes to cholesterol levels, insulin resistance, and C-reactive protein (CRP). The major limitation of this study is that there were too few cardiovascular-related clinical events to evaluate MHT’s affect on CVD development. Overall, MHT does not appear to prevent the progression of atherosclerosis in menopausal women.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

In-Depth [randomized controlled trial]: Previous studies of menopausal women and CVD risk were performed in older women.  To determine if the cardioprotective effect of MHT was age-dependent, this trial only included women within 3 years of their last menses. In those given HMT, they received either oral conjugated equine estrogens (o-CEE) or transdermal 17β-estradiol (t-E2), each with oral progesterone for four years. The differences in CIMT between o-CEE and t-E2 to placebo were 0.0008mm/y [95%CI=-0.0012-0.0029] and 0.0005mm/y [95%CI=-0.0016-0.0026], neither of which was significant. The percent of those who had an increase in CAC scores with age were also similar, o-CEE with 17.4%, t-E2 with 18.9%, and placebo with 21.0%. o-CEE decreased LDL and increased HDL, CRP, and SHBG, whereas t-E2 decreased total lipoprotein and insulin levels, as well as the Homeostasis Model Assessment of Insulin Resistance score. HMT was verified to be able to improve menopausal symptoms and increase estrogen levels. This study shows that recently menopausal women may only have small improvements to some CVD risk factors, but not overall atherosclerosis.

RELATED REPORTS

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

Unsweetened coffee consumption is associated with reduced risk of mortality

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

More from this author: Less frequent echocardiography for cancer survivors may be more cost effectivePrenatal screening and postnatal prophylaxis may prevent vertical Hep B transmissionLow-strength evidence for hepatocellular carcinoma screening in liver diseaseEfavirenz (Sustiva) for HIV patients may increase risk of suicideSocial integration may reduce suicide risk in male health professionals 

Image: PD 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: atherosclerosiscardiovascular diseasehormonepostmenopausal
Previous Post

2 Minute Medicine Rewind July 20 – July 27, 2014

Next Post

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

RelatedReports

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Cardiology

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

June 24, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

June 18, 2022
Early language exposure is predictive of language skills and IQ in school-age children
Cardiology

Late and moderate preterm birth associated with increased cardiometabolic risk scores in young children

June 1, 2022
Next Post
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Vitamin and supplement data remains limited, may provide no benefit

Vitamin D not effective in reducing recurrent bacterial vaginosis

2 Minute Medicine Rewind December 31-January 6, 2013

Functional connectivity similar between autosomal dominant and late onset Alzheimer Disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.